Regencell Bioscience Holdings Limited
Regencell Bioscience Holdings Limited RGC Peers
See (RGC) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| RGC | $17.04 | -21.60% | 10B | -2019.00 | -$0.01 | N/A |
| ZTS | $156.05 | -0.75% | 69.4B | 28.02 | $5.56 | +1.20% |
| TAK | $15.11 | +0.90% | 47.4B | 65.52 | $0.23 | +3.91% |
| HLN | $10.38 | -1.16% | 46.9B | 24.24 | $0.43 | +1.12% |
| TEVA | $16.72 | -1.68% | 19B | -14.42 | -$1.15 | N/A |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| RDY | $15.06 | -2.84% | 12.8B | 19.65 | $0.78 | +0.62% |
| NBIX | $126.27 | -1.19% | 12.5B | 42.96 | $2.95 | N/A |
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
| VTRS | $8.98 | +0.98% | 10.7B | -2.87 | -$3.18 | +5.29% |
Stock Comparison
RGC vs ZTS Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, ZTS has a market cap of 69.4B. Regarding current trading prices, RGC is priced at $17.04, while ZTS trades at $156.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas ZTS's P/E ratio is 28.02. In terms of profitability, RGC's ROE is -0.25%, compared to ZTS's ROE of +0.51%. Regarding short-term risk, RGC is more volatile compared to ZTS. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs TAK Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, TAK has a market cap of 47.4B. Regarding current trading prices, RGC is priced at $17.04, while TAK trades at $15.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas TAK's P/E ratio is 65.52. In terms of profitability, RGC's ROE is -0.25%, compared to TAK's ROE of +0.04%. Regarding short-term risk, RGC is more volatile compared to TAK. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs HLN Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, HLN has a market cap of 46.9B. Regarding current trading prices, RGC is priced at $17.04, while HLN trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas HLN's P/E ratio is 24.24. In terms of profitability, RGC's ROE is -0.25%, compared to HLN's ROE of +0.09%. Regarding short-term risk, RGC is more volatile compared to HLN. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs TEVA Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, TEVA has a market cap of 19B. Regarding current trading prices, RGC is priced at $17.04, while TEVA trades at $16.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas TEVA's P/E ratio is -14.42. In terms of profitability, RGC's ROE is -0.25%, compared to TEVA's ROE of -0.21%. Regarding short-term risk, RGC is more volatile compared to TEVA. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs ITCI Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, RGC is priced at $17.04, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas ITCI's P/E ratio is -180.64. In terms of profitability, RGC's ROE is -0.25%, compared to ITCI's ROE of -0.07%. Regarding short-term risk, RGC is more volatile compared to ITCI. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs RDY Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, RDY has a market cap of 12.8B. Regarding current trading prices, RGC is priced at $17.04, while RDY trades at $15.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas RDY's P/E ratio is 19.65. In terms of profitability, RGC's ROE is -0.25%, compared to RDY's ROE of +0.18%. Regarding short-term risk, RGC is more volatile compared to RDY. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs NBIX Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, NBIX has a market cap of 12.5B. Regarding current trading prices, RGC is priced at $17.04, while NBIX trades at $126.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas NBIX's P/E ratio is 42.96. In terms of profitability, RGC's ROE is -0.25%, compared to NBIX's ROE of +0.12%. Regarding short-term risk, RGC is more volatile compared to NBIX. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs CTLT Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, RGC is priced at $17.04, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas CTLT's P/E ratio is -27.84. In terms of profitability, RGC's ROE is -0.25%, compared to CTLT's ROE of -0.11%. Regarding short-term risk, RGC is more volatile compared to CTLT. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs VTRS Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, VTRS has a market cap of 10.7B. Regarding current trading prices, RGC is priced at $17.04, while VTRS trades at $8.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas VTRS's P/E ratio is -2.87. In terms of profitability, RGC's ROE is -0.25%, compared to VTRS's ROE of -0.21%. Regarding short-term risk, RGC is more volatile compared to VTRS. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs ELAN Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, ELAN has a market cap of 7.1B. Regarding current trading prices, RGC is priced at $17.04, while ELAN trades at $14.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas ELAN's P/E ratio is 19.06. In terms of profitability, RGC's ROE is -0.25%, compared to ELAN's ROE of +0.06%. Regarding short-term risk, RGC is more volatile compared to ELAN. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs LNTH Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, LNTH has a market cap of 5.6B. Regarding current trading prices, RGC is priced at $17.04, while LNTH trades at $81.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas LNTH's P/E ratio is 23.00. In terms of profitability, RGC's ROE is -0.25%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, RGC is more volatile compared to LNTH. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs AMRX Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, AMRX has a market cap of 3.8B. Regarding current trading prices, RGC is priced at $17.04, while AMRX trades at $8.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas AMRX's P/E ratio is -203.25. In terms of profitability, RGC's ROE is -0.25%, compared to AMRX's ROE of -0.07%. Regarding short-term risk, RGC is more volatile compared to AMRX. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs PRGO Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, PRGO has a market cap of 3.7B. Regarding current trading prices, RGC is priced at $17.04, while PRGO trades at $26.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas PRGO's P/E ratio is -22.14. In terms of profitability, RGC's ROE is -0.25%, compared to PRGO's ROE of -0.04%. Regarding short-term risk, RGC is more volatile compared to PRGO. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs ALVO Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, ALVO has a market cap of 2.8B. Regarding current trading prices, RGC is priced at $17.04, while ALVO trades at $9.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas ALVO's P/E ratio is 25.46. In terms of profitability, RGC's ROE is -0.25%, compared to ALVO's ROE of -0.23%. Regarding short-term risk, RGC is more volatile compared to ALVO. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs ALVOW Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, ALVOW has a market cap of 2.7B. Regarding current trading prices, RGC is priced at $17.04, while ALVOW trades at $1.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas ALVOW's P/E ratio is N/A. In terms of profitability, RGC's ROE is -0.25%, compared to ALVOW's ROE of -0.23%. Regarding short-term risk, RGC is more volatile compared to ALVOW. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs HCM Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, HCM has a market cap of 2.7B. Regarding current trading prices, RGC is priced at $17.04, while HCM trades at $15.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas HCM's P/E ratio is 76.70. In terms of profitability, RGC's ROE is -0.25%, compared to HCM's ROE of +0.05%. Regarding short-term risk, RGC is more volatile compared to HCM. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs BHC Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, BHC has a market cap of 2.4B. Regarding current trading prices, RGC is priced at $17.04, while BHC trades at $6.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas BHC's P/E ratio is -53.42. In terms of profitability, RGC's ROE is -0.25%, compared to BHC's ROE of +0.05%. Regarding short-term risk, RGC is more volatile compared to BHC. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs BGM Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, BGM has a market cap of 2.4B. Regarding current trading prices, RGC is priced at $17.04, while BGM trades at $12.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas BGM's P/E ratio is -64.10. In terms of profitability, RGC's ROE is -0.25%, compared to BGM's ROE of -0.03%. Regarding short-term risk, RGC is more volatile compared to BGM. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs DCPH Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, RGC is priced at $17.04, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas DCPH's P/E ratio is -11.58. In terms of profitability, RGC's ROE is -0.25%, compared to DCPH's ROE of -0.28%. Regarding short-term risk, RGC is more volatile compared to DCPH. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs EMBCV Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, RGC is priced at $17.04, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas EMBCV's P/E ratio is N/A. In terms of profitability, RGC's ROE is -0.25%, compared to EMBCV's ROE of -0.07%. Regarding short-term risk, RGC is more volatile compared to EMBCV. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs SUPN Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, SUPN has a market cap of 1.7B. Regarding current trading prices, RGC is priced at $17.04, while SUPN trades at $31.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas SUPN's P/E ratio is 28.11. In terms of profitability, RGC's ROE is -0.25%, compared to SUPN's ROE of +0.06%. Regarding short-term risk, RGC is more volatile compared to SUPN. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs INDV Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, INDV has a market cap of 1.7B. Regarding current trading prices, RGC is priced at $17.04, while INDV trades at $13.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas INDV's P/E ratio is -273.80. In terms of profitability, RGC's ROE is -0.25%, compared to INDV's ROE of -0.01%. Regarding short-term risk, RGC is more volatile compared to INDV. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs TARO Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, RGC is priced at $17.04, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas TARO's P/E ratio is 30.05. In terms of profitability, RGC's ROE is -0.25%, compared to TARO's ROE of +0.02%. Regarding short-term risk, RGC is more volatile compared to TARO. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs EVO Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, EVO has a market cap of 1.5B. Regarding current trading prices, RGC is priced at $17.04, while EVO trades at $4.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas EVO's P/E ratio is -6.30. In terms of profitability, RGC's ROE is -0.25%, compared to EVO's ROE of -0.22%. Regarding short-term risk, RGC is more volatile compared to EVO. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs ANIP Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, ANIP has a market cap of 1.4B. Regarding current trading prices, RGC is priced at $17.04, while ANIP trades at $65.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas ANIP's P/E ratio is -55.77. In terms of profitability, RGC's ROE is -0.25%, compared to ANIP's ROE of -0.05%. Regarding short-term risk, RGC is more volatile compared to ANIP. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs DVAX Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, DVAX has a market cap of 1.2B. Regarding current trading prices, RGC is priced at $17.04, while DVAX trades at $9.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas DVAX's P/E ratio is -19.87. In terms of profitability, RGC's ROE is -0.25%, compared to DVAX's ROE of -0.10%. Regarding short-term risk, RGC is more volatile compared to DVAX. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs HROW Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, HROW has a market cap of 1.2B. Regarding current trading prices, RGC is priced at $17.04, while HROW trades at $31.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas HROW's P/E ratio is -51.39. In terms of profitability, RGC's ROE is -0.25%, compared to HROW's ROE of -0.36%. Regarding short-term risk, RGC is more volatile compared to HROW. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs PCRX Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, PCRX has a market cap of 1.1B. Regarding current trading prices, RGC is priced at $17.04, while PCRX trades at $23.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas PCRX's P/E ratio is -10.58. In terms of profitability, RGC's ROE is -0.25%, compared to PCRX's ROE of -0.13%. Regarding short-term risk, RGC is more volatile compared to PCRX. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs AMPH Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, AMPH has a market cap of 1.1B. Regarding current trading prices, RGC is priced at $17.04, while AMPH trades at $23.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas AMPH's P/E ratio is 8.40. In terms of profitability, RGC's ROE is -0.25%, compared to AMPH's ROE of +0.19%. Regarding short-term risk, RGC is more volatile compared to AMPH. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs PAHC Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, PAHC has a market cap of 1B. Regarding current trading prices, RGC is priced at $17.04, while PAHC trades at $25.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas PAHC's P/E ratio is 32.21. In terms of profitability, RGC's ROE is -0.25%, compared to PAHC's ROE of +0.12%. Regarding short-term risk, RGC is more volatile compared to PAHC. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs COLL Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, COLL has a market cap of 960.7M. Regarding current trading prices, RGC is priced at $17.04, while COLL trades at $29.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas COLL's P/E ratio is 24.50. In terms of profitability, RGC's ROE is -0.25%, compared to COLL's ROE of +0.19%. Regarding short-term risk, RGC is more volatile compared to COLL. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs PETQ Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, RGC is priced at $17.04, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas PETQ's P/E ratio is 83.73. In terms of profitability, RGC's ROE is -0.25%, compared to PETQ's ROE of +0.05%. Regarding short-term risk, RGC is more volatile compared to PETQ. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs AVDL Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, AVDL has a market cap of 900.1M. Regarding current trading prices, RGC is priced at $17.04, while AVDL trades at $9.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas AVDL's P/E ratio is -35.73. In terms of profitability, RGC's ROE is -0.25%, compared to AVDL's ROE of -0.36%. Regarding short-term risk, RGC is more volatile compared to AVDL. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs CRON Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, CRON has a market cap of 736.2M. Regarding current trading prices, RGC is priced at $17.04, while CRON trades at $1.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas CRON's P/E ratio is 13.64. In terms of profitability, RGC's ROE is -0.25%, compared to CRON's ROE of +0.05%. Regarding short-term risk, RGC is more volatile compared to CRON. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs EOLS Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, EOLS has a market cap of 600.3M. Regarding current trading prices, RGC is priced at $17.04, while EOLS trades at $9.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas EOLS's P/E ratio is -10.46. In terms of profitability, RGC's ROE is -0.25%, compared to EOLS's ROE of -9.32%. Regarding short-term risk, RGC is more volatile compared to EOLS. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs BDSI Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, RGC is priced at $17.04, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas BDSI's P/E ratio is 6.82. In terms of profitability, RGC's ROE is -0.25%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, RGC is more volatile compared to BDSI. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs EMBC Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, EMBC has a market cap of 541.8M. Regarding current trading prices, RGC is priced at $17.04, while EMBC trades at $9.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas EMBC's P/E ratio is 10.42. In terms of profitability, RGC's ROE is -0.25%, compared to EMBC's ROE of -0.07%. Regarding short-term risk, RGC is more volatile compared to EMBC. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs SIGA Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, SIGA has a market cap of 468.7M. Regarding current trading prices, RGC is priced at $17.04, while SIGA trades at $6.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas SIGA's P/E ratio is 9.79. In terms of profitability, RGC's ROE is -0.25%, compared to SIGA's ROE of +0.25%. Regarding short-term risk, RGC is more volatile compared to SIGA. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs ORGO Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, ORGO has a market cap of 457.9M. Regarding current trading prices, RGC is priced at $17.04, while ORGO trades at $3.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas ORGO's P/E ratio is -22.56. In terms of profitability, RGC's ROE is -0.25%, compared to ORGO's ROE of -0.06%. Regarding short-term risk, RGC is more volatile compared to ORGO. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs KMDA Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, KMDA has a market cap of 452M. Regarding current trading prices, RGC is priced at $17.04, while KMDA trades at $7.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas KMDA's P/E ratio is 28.07. In terms of profitability, RGC's ROE is -0.25%, compared to KMDA's ROE of +0.06%. Regarding short-term risk, RGC is more volatile compared to KMDA. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs TLRY Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, TLRY has a market cap of 422.9M. Regarding current trading prices, RGC is priced at $17.04, while TLRY trades at $0.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas TLRY's P/E ratio is -0.39. In terms of profitability, RGC's ROE is -0.25%, compared to TLRY's ROE of -0.29%. Regarding short-term risk, RGC is more volatile compared to TLRY. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs EBS Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, EBS has a market cap of 371.3M. Regarding current trading prices, RGC is priced at $17.04, while EBS trades at $6.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas EBS's P/E ratio is -2.65. In terms of profitability, RGC's ROE is -0.25%, compared to EBS's ROE of -0.27%. Regarding short-term risk, RGC is more volatile compared to EBS. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs ZYBT Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, ZYBT has a market cap of 334.1M. Regarding current trading prices, RGC is priced at $17.04, while ZYBT trades at $6.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas ZYBT's P/E ratio is 117.50. In terms of profitability, RGC's ROE is -0.25%, compared to ZYBT's ROE of +0.11%. Regarding short-term risk, RGC is less volatile compared to ZYBT. This indicates potentially lower risk in terms of short-term price fluctuations for RGC.
RGC vs AQST Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, AQST has a market cap of 322.8M. Regarding current trading prices, RGC is priced at $17.04, while AQST trades at $3.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas AQST's P/E ratio is -5.60. In terms of profitability, RGC's ROE is -0.25%, compared to AQST's ROE of +1.07%. Regarding short-term risk, RGC is more volatile compared to AQST. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs SNDL Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, SNDL has a market cap of 321.6M. Regarding current trading prices, RGC is priced at $17.04, while SNDL trades at $1.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas SNDL's P/E ratio is -4.17. In terms of profitability, RGC's ROE is -0.25%, compared to SNDL's ROE of -0.09%. Regarding short-term risk, RGC is more volatile compared to SNDL. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs LFCR Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, LFCR has a market cap of 304.7M. Regarding current trading prices, RGC is priced at $17.04, while LFCR trades at $8.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas LFCR's P/E ratio is -5.60. In terms of profitability, RGC's ROE is -0.25%, compared to LFCR's ROE of -2.64%. Regarding short-term risk, RGC is more volatile compared to LFCR. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs ALIM Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, RGC is priced at $17.04, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas ALIM's P/E ratio is 5.28. In terms of profitability, RGC's ROE is -0.25%, compared to ALIM's ROE of -0.32%. Regarding short-term risk, RGC is more volatile compared to ALIM. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs TKNO Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, TKNO has a market cap of 273.1M. Regarding current trading prices, RGC is priced at $17.04, while TKNO trades at $5.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas TKNO's P/E ratio is -11.11. In terms of profitability, RGC's ROE is -0.25%, compared to TKNO's ROE of -0.28%. Regarding short-term risk, RGC is more volatile compared to TKNO. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs LNDC Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, RGC is priced at $17.04, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas LNDC's P/E ratio is -4.04. In terms of profitability, RGC's ROE is -0.25%, compared to LNDC's ROE of +2.28%. Regarding short-term risk, RGC is more volatile compared to LNDC. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs CGC Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, CGC has a market cap of 257.5M. Regarding current trading prices, RGC is priced at $17.04, while CGC trades at $1.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas CGC's P/E ratio is -0.30. In terms of profitability, RGC's ROE is -0.25%, compared to CGC's ROE of -1.13%. Regarding short-term risk, RGC is more volatile compared to CGC. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs ACB Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, ACB has a market cap of 233.5M. Regarding current trading prices, RGC is priced at $17.04, while ACB trades at $4.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas ACB's P/E ratio is 22.39. In terms of profitability, RGC's ROE is -0.25%, compared to ACB's ROE of +0.00%. Regarding short-term risk, RGC is more volatile compared to ACB. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs TYHT Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, RGC is priced at $17.04, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas TYHT's P/E ratio is -1.61. In terms of profitability, RGC's ROE is -0.25%, compared to TYHT's ROE of -1.41%. Regarding short-term risk, RGC is more volatile compared to TYHT. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs ESPR Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, ESPR has a market cap of 202.2M. Regarding current trading prices, RGC is priced at $17.04, while ESPR trades at $1.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas ESPR's P/E ratio is -1.20. In terms of profitability, RGC's ROE is -0.25%, compared to ESPR's ROE of +0.40%. Regarding short-term risk, RGC is more volatile compared to ESPR. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs OGI Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, OGI has a market cap of 186.8M. Regarding current trading prices, RGC is priced at $17.04, while OGI trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas OGI's P/E ratio is 10.73. In terms of profitability, RGC's ROE is -0.25%, compared to OGI's ROE of +0.05%. Regarding short-term risk, RGC is more volatile compared to OGI. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs REPH Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, RGC is priced at $17.04, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas REPH's P/E ratio is -8.04. In terms of profitability, RGC's ROE is -0.25%, compared to REPH's ROE of -0.22%. Regarding short-term risk, RGC is more volatile compared to REPH. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs DERM Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, DERM has a market cap of 163.1M. Regarding current trading prices, RGC is priced at $17.04, while DERM trades at $7.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas DERM's P/E ratio is -18.92. In terms of profitability, RGC's ROE is -0.25%, compared to DERM's ROE of -0.52%. Regarding short-term risk, RGC is more volatile compared to DERM. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs BIOA Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, BIOA has a market cap of 156.3M. Regarding current trading prices, RGC is priced at $17.04, while BIOA trades at $4.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas BIOA's P/E ratio is -2.20. In terms of profitability, RGC's ROE is -0.25%, compared to BIOA's ROE of -0.38%. Regarding short-term risk, RGC is more volatile compared to BIOA. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs IRWD Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, IRWD has a market cap of 125.9M. Regarding current trading prices, RGC is priced at $17.04, while IRWD trades at $0.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas IRWD's P/E ratio is -4.10. In terms of profitability, RGC's ROE is -0.25%, compared to IRWD's ROE of +0.10%. Regarding short-term risk, RGC is more volatile compared to IRWD. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs CRDL Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, CRDL has a market cap of 121.1M. Regarding current trading prices, RGC is priced at $17.04, while CRDL trades at $1.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas CRDL's P/E ratio is -4.31. In terms of profitability, RGC's ROE is -0.25%, compared to CRDL's ROE of -2.08%. Regarding short-term risk, RGC is more volatile compared to CRDL. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs SCTL Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, RGC is priced at $17.04, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas SCTL's P/E ratio is -7.86. In terms of profitability, RGC's ROE is -0.25%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, RGC is more volatile compared to SCTL. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs PROC Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, PROC has a market cap of 114M. Regarding current trading prices, RGC is priced at $17.04, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas PROC's P/E ratio is 1.53. In terms of profitability, RGC's ROE is -0.25%, compared to PROC's ROE of -2.22%. Regarding short-term risk, RGC is more volatile compared to PROC. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs THTX Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, THTX has a market cap of 108.1M. Regarding current trading prices, RGC is priced at $17.04, while THTX trades at $2.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas THTX's P/E ratio is -33.57. In terms of profitability, RGC's ROE is -0.25%, compared to THTX's ROE of +0.16%. Regarding short-term risk, RGC is more volatile compared to THTX. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs OPTN Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, RGC is priced at $17.04, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas OPTN's P/E ratio is -4.42. In terms of profitability, RGC's ROE is -0.25%, compared to OPTN's ROE of +0.64%. Regarding short-term risk, RGC is more volatile compared to OPTN. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs ZOM Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, RGC is priced at $17.04, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas ZOM's P/E ratio is -1.62. In terms of profitability, RGC's ROE is -0.25%, compared to ZOM's ROE of -0.55%. Regarding short-term risk, RGC is more volatile compared to ZOM. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs GRVI Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, RGC is priced at $17.04, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas GRVI's P/E ratio is 26.05. In terms of profitability, RGC's ROE is -0.25%, compared to GRVI's ROE of -5.25%. Regarding short-term risk, RGC is more volatile compared to GRVI. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs INCR Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, INCR has a market cap of 70.3M. Regarding current trading prices, RGC is priced at $17.04, while INCR trades at $1.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas INCR's P/E ratio is -3.55. In terms of profitability, RGC's ROE is -0.25%, compared to INCR's ROE of -0.07%. Regarding short-term risk, RGC is more volatile compared to INCR. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs ZYNE Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, RGC is priced at $17.04, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, RGC's ROE is -0.25%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, RGC is more volatile compared to ZYNE. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs SSIC Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, RGC is priced at $17.04, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas SSIC's P/E ratio is 11.93. In terms of profitability, RGC's ROE is -0.25%, compared to SSIC's ROE of +0.03%. Regarding short-term risk, RGC is more volatile compared to SSIC. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs ASRT Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, ASRT has a market cap of 62.3M. Regarding current trading prices, RGC is priced at $17.04, while ASRT trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas ASRT's P/E ratio is -2.03. In terms of profitability, RGC's ROE is -0.25%, compared to ASRT's ROE of -0.24%. Regarding short-term risk, RGC is more volatile compared to ASRT. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs VLNS Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, RGC is priced at $17.04, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas VLNS's P/E ratio is -1.03. In terms of profitability, RGC's ROE is -0.25%, compared to VLNS's ROE of N/A. Regarding short-term risk, RGC is more volatile compared to VLNS. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs QNTM Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, QNTM has a market cap of 61.4M. Regarding current trading prices, RGC is priced at $17.04, while QNTM trades at $22.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas QNTM's P/E ratio is -1.60. In terms of profitability, RGC's ROE is -0.25%, compared to QNTM's ROE of -1.88%. Regarding short-term risk, RGC is more volatile compared to QNTM. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs JUPW Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, RGC is priced at $17.04, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas JUPW's P/E ratio is -2.41. In terms of profitability, RGC's ROE is -0.25%, compared to JUPW's ROE of -9.40%. Regarding short-term risk, RGC is more volatile compared to JUPW. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs SXTC Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, SXTC has a market cap of 45.3M. Regarding current trading prices, RGC is priced at $17.04, while SXTC trades at $1.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas SXTC's P/E ratio is 0.01. In terms of profitability, RGC's ROE is -0.25%, compared to SXTC's ROE of +0.47%. Regarding short-term risk, RGC is more volatile compared to SXTC. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs CPIX Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, CPIX has a market cap of 40.1M. Regarding current trading prices, RGC is priced at $17.04, while CPIX trades at $2.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas CPIX's P/E ratio is -11.17. In terms of profitability, RGC's ROE is -0.25%, compared to CPIX's ROE of -0.13%. Regarding short-term risk, RGC is more volatile compared to CPIX. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs QLI Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, RGC is priced at $17.04, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas QLI's P/E ratio is -4.92. In terms of profitability, RGC's ROE is -0.25%, compared to QLI's ROE of -0.16%. Regarding short-term risk, RGC is more volatile compared to QLI. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs EGRX Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, EGRX has a market cap of 35M. Regarding current trading prices, RGC is priced at $17.04, while EGRX trades at $2.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas EGRX's P/E ratio is 3.18. In terms of profitability, RGC's ROE is -0.25%, compared to EGRX's ROE of +0.17%. Regarding short-term risk, RGC is more volatile compared to EGRX. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs KALA Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, KALA has a market cap of 33.7M. Regarding current trading prices, RGC is priced at $17.04, while KALA trades at $4.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas KALA's P/E ratio is -0.71. In terms of profitability, RGC's ROE is -0.25%, compared to KALA's ROE of -3.69%. Regarding short-term risk, RGC is less volatile compared to KALA. This indicates potentially lower risk in terms of short-term price fluctuations for RGC.
RGC vs HEXO Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, RGC is priced at $17.04, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas HEXO's P/E ratio is -0.26. In terms of profitability, RGC's ROE is -0.25%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, RGC is more volatile compared to HEXO. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs SCYX Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, SCYX has a market cap of 28.7M. Regarding current trading prices, RGC is priced at $17.04, while SCYX trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas SCYX's P/E ratio is -1.32. In terms of profitability, RGC's ROE is -0.25%, compared to SCYX's ROE of -0.48%. Regarding short-term risk, RGC is more volatile compared to SCYX. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs RMTI Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, RMTI has a market cap of 27.6M. Regarding current trading prices, RGC is priced at $17.04, while RMTI trades at $0.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas RMTI's P/E ratio is -80.90. In terms of profitability, RGC's ROE is -0.25%, compared to RMTI's ROE of -0.01%. Regarding short-term risk, RGC is more volatile compared to RMTI. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs CYTH Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, RGC is priced at $17.04, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas CYTH's P/E ratio is -0.80. In terms of profitability, RGC's ROE is -0.25%, compared to CYTH's ROE of +7.50%. Regarding short-term risk, RGC is more volatile compared to CYTH. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs IXHL Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, IXHL has a market cap of 19.6M. Regarding current trading prices, RGC is priced at $17.04, while IXHL trades at $0.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas IXHL's P/E ratio is -0.17. In terms of profitability, RGC's ROE is -0.25%, compared to IXHL's ROE of -2.03%. Regarding short-term risk, RGC is more volatile compared to IXHL. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs DRRX Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, DRRX has a market cap of 19.3M. Regarding current trading prices, RGC is priced at $17.04, while DRRX trades at $0.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas DRRX's P/E ratio is -1.29. In terms of profitability, RGC's ROE is -0.25%, compared to DRRX's ROE of -0.93%. Regarding short-term risk, RGC is more volatile compared to DRRX. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs GELS Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, GELS has a market cap of 17.7M. Regarding current trading prices, RGC is priced at $17.04, while GELS trades at $1.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas GELS's P/E ratio is -7.83. In terms of profitability, RGC's ROE is -0.25%, compared to GELS's ROE of -0.21%. Regarding short-term risk, RGC is more volatile compared to GELS. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs ACRX Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, RGC is priced at $17.04, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas ACRX's P/E ratio is -0.31. In terms of profitability, RGC's ROE is -0.25%, compared to ACRX's ROE of -2.49%. Regarding short-term risk, RGC is more volatile compared to ACRX. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs PRPH Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, PRPH has a market cap of 14.2M. Regarding current trading prices, RGC is priced at $17.04, while PRPH trades at $0.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas PRPH's P/E ratio is -0.15. In terms of profitability, RGC's ROE is -0.25%, compared to PRPH's ROE of -1.65%. Regarding short-term risk, RGC is more volatile compared to PRPH. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs FLGC Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, FLGC has a market cap of 14.2M. Regarding current trading prices, RGC is priced at $17.04, while FLGC trades at $0.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas FLGC's P/E ratio is -0.65. In terms of profitability, RGC's ROE is -0.25%, compared to FLGC's ROE of -2.55%. Regarding short-term risk, RGC is more volatile compared to FLGC. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs TXMD Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, TXMD has a market cap of 13.5M. Regarding current trading prices, RGC is priced at $17.04, while TXMD trades at $1.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas TXMD's P/E ratio is -6.16. In terms of profitability, RGC's ROE is -0.25%, compared to TXMD's ROE of -0.08%. Regarding short-term risk, RGC is more volatile compared to TXMD. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs AYTU Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, AYTU has a market cap of 12.8M. Regarding current trading prices, RGC is priced at $17.04, while AYTU trades at $2.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas AYTU's P/E ratio is -1.40. In terms of profitability, RGC's ROE is -0.25%, compared to AYTU's ROE of +0.05%. Regarding short-term risk, RGC is more volatile compared to AYTU. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs COSM Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, COSM has a market cap of 12.8M. Regarding current trading prices, RGC is priced at $17.04, while COSM trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas COSM's P/E ratio is -0.40. In terms of profitability, RGC's ROE is -0.25%, compared to COSM's ROE of -0.51%. Regarding short-term risk, RGC is more volatile compared to COSM. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs AGRX Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, RGC is priced at $17.04, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas AGRX's P/E ratio is -0.89. In terms of profitability, RGC's ROE is -0.25%, compared to AGRX's ROE of +0.93%. Regarding short-term risk, RGC is more volatile compared to AGRX. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs TLPH Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, TLPH has a market cap of 9M. Regarding current trading prices, RGC is priced at $17.04, while TLPH trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas TLPH's P/E ratio is -1.00. In terms of profitability, RGC's ROE is -0.25%, compared to TLPH's ROE of -1.29%. Regarding short-term risk, RGC is more volatile compared to TLPH. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs IMCC Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, IMCC has a market cap of 8.6M. Regarding current trading prices, RGC is priced at $17.04, while IMCC trades at $2.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas IMCC's P/E ratio is -2.01. In terms of profitability, RGC's ROE is -0.25%, compared to IMCC's ROE of -1.52%. Regarding short-term risk, RGC is more volatile compared to IMCC. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs SBFMW Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, SBFMW has a market cap of 8.2M. Regarding current trading prices, RGC is priced at $17.04, while SBFMW trades at $0.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas SBFMW's P/E ratio is -0.11. In terms of profitability, RGC's ROE is -0.25%, compared to SBFMW's ROE of -0.21%. Regarding short-term risk, RGC is more volatile compared to SBFMW. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs NLTX Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, RGC is priced at $17.04, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas NLTX's P/E ratio is -0.28. In terms of profitability, RGC's ROE is -0.25%, compared to NLTX's ROE of -0.49%. Regarding short-term risk, RGC is more volatile compared to NLTX. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs YCBD Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, YCBD has a market cap of 7.8M. Regarding current trading prices, RGC is priced at $17.04, while YCBD trades at $0.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas YCBD's P/E ratio is 0.01. In terms of profitability, RGC's ROE is -0.25%, compared to YCBD's ROE of -0.01%. Regarding short-term risk, RGC is more volatile compared to YCBD. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs LCI Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, RGC is priced at $17.04, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas LCI's P/E ratio is -0.04. In terms of profitability, RGC's ROE is -0.25%, compared to LCI's ROE of +1.66%. Regarding short-term risk, RGC is more volatile compared to LCI. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs BGXX Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, BGXX has a market cap of 7.3M. Regarding current trading prices, RGC is priced at $17.04, while BGXX trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas BGXX's P/E ratio is -0.76. In terms of profitability, RGC's ROE is -0.25%, compared to BGXX's ROE of -0.88%. Regarding short-term risk, RGC is more volatile compared to BGXX. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.
RGC vs ADMP Comparison
RGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGC stands at 10B. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, RGC is priced at $17.04, while ADMP trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGC currently has a P/E ratio of -2019.00, whereas ADMP's P/E ratio is -0.08. In terms of profitability, RGC's ROE is -0.25%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, RGC is more volatile compared to ADMP. This indicates potentially higher risk in terms of short-term price fluctuations for RGC.